Promising Phase 2 Results for PL8177 in Treating Ulcerative Colitis Show Clinical Remission in Patients Palatin Technologies has reported significant outcomes from its Phase 2 study of PL8177 for ulcerative colitis, with clinical remission achieved in a third of patients, presenting a potential alternative to traditional therapies.

Promising Phase 2 Results for PL8177 in Treating Ulcerative Colitis Show Clinical Remission in Patients #United_States #Ulcerative_Colitis #Palatin_Technologies #PL8177 #Cranbury

Palatin Completes Enrollment for Phase 2 Trial of New Ulcerative Colitis Treatment, PL8177 Palatin Technologies has completed patient enrollment in a Phase 2 trial for PL8177, an innovative treatment for ulcerative colitis, aiming to provide an effective alternative to current therapies.

Palatin Completes Enrollment for Phase 2 Trial of New Ulcerative Colitis Treatment, PL8177 #USA #Ulcerative_Colitis #Palatin_Technologies #PL8177 #Cranbury